Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
- Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data
- Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started
- First patient in clinical study dosed with the second ATAC candidate HDP-102 in the non-Hodgkin lymphoma (NHL) indication
- Amendment of contract with HealthCare Royalty; payment of USD 20 million received
- A further payment of USD 70 million is expected upon approval of the TLX250-CDx diagnostic at the end of August 2025, which will significantly extend the current cash reach
- Karl Benedikt Biesinger and Dr. Klaus Schollmeier elected as new members of the Supervisory Board
- Financial figures in line with planning
Ladenburg, Germany, 10 July 2025 – Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2025 (1 December 2024 – 31 May 2025) and reported about the course of business.
